Podcasts

Join Professor Ed Vital, Dr Guillermo J. Pons-Estel, Professor Richard Furie and Professor Chris Edwards on the Lupus Forum for their discussion of the recent webinar “Early use of advanced therapies in lupus”. Watch them discuss key highlights from the webinar, including limitations of SoC, insights from clinical trials and strategies for early intervention with advanced therapies.

Join Professor Chris Edwards and Dr Alice Mason as they discuss EULAR recommendations for a core dataset in SLE and the efficacy and safety of upadacitinib as a monotherapy or in combination with elsubrutinib for SLE. This podcast provides a valuable framework for guiding therapeutic decisions in SLE and also supporting clinical care and translational/observational research.

Professor Eric Morand and Professor Rangi Kandane-Rathnayake discuss the therapeutic strategies and emerging treatments in SLE and LN. This podcast provides a valuable framework for guiding therapeutic decisions for rare SLE manifestations where the available recommendations might be insufficient or inapplicable. The efficacy, PK and safety of iscalimab versus placebo as add-on to SoC therapy in patients with biopsy-proven active proliferative LN is also reported.

Join Professors Ed Vital and Maria Dall’Era, and Doctor Guillermo J. Pons-Estel for an expert-led discussion focusing on the latest ACR 2025 SLE Guidelines. This podcast provides an overview of the latest treatment recommendations, as well as ungraded, consensus-based good practice statements that are applicable to children and adults with SLE.

Join Professor Brad Rovin for an expert-led discussion focused on emerging therapies and renal outcomes in LN. This podcast will provide an overview of the effect of long-term voclosporin treatment on renal histology in patients with active LN with repeat renal biopsies and explore how BCMA-targeted CAR T-cell therapy can effectively induce disease remission in refractory LN.

Join Professors Ed Vital and Michelle Kahlenberg as they delve into the role of the cGAS pathway in systemic lupus erythematosus (SLE). This engaging discussion covers the pathway’s relevance in disease, recent clinical trial updates on cGAS inhibitors, and their potential role in the future treatment of SLE.